We are currently conducting clinical trials on the following skin conditions:
For more information about these clinical studies and your eligibility, please contact
Non-Segmental Vitiligo Research Trial (63 Weeks) Adults aged 18 years or older with a clinical diagnosis of non-segmental vitiligo (bilateral and symmetrical loss of skin pigment), may qualify to participate.
Individuals must have a loss of skin pigment on the face and body, along with at least one active vitiligo lesion. Individuals must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.
Participants will receive investigational topical medication (active study drug) or placebo, during the initial treatment period. In the extension period, all subjects will receive active study drug. Study medication and study-related procedures will be provided at no cost. Reimbursement for study-related expenses will also be provided. Study participation will last about 63 weeks and involve about 11 visits to the study centre
Adults aged 18-75 years old with moderate to severe plaque psoriasis (with or without psoriatic arthritis) for at least 6 months, may qualify to participate.
Individuals must have stable disease for at least 2 months, with psoriatic involvement of 10% or more body surface area. There must also be no known history of latent or active tuberculosis (TB); testing will occur at screening. Participants will be part of one of two groups: the continued-use group (receiving adalimumab) OR the switching group (receiving investigational medication (active study drug) and adalimumab), via subcutaneous injection.
Study medication and study-related assessments will be provided at no cost. Reimbursement for reasonable study-related expenses will also be provided. Study participation will last about 36 weeks and involve about 23 visits to the study centre.
Adoring is a phase 3 clinical study evaluating the safety and effectiveness of tapinarof cream,1% for the topical treatment of moderate to severe eczema in adults and children ages 2 and above.
Eczema, also known as atopic dermatitis (AD), is an incurable, chronic condition. Up to 30% of children may be affected by eczema at some point.
Between 2% to 10% of adults currently live with eczema. Although several treatment options are available, there is currently no safe and effective topical treatment for eczema that can be applied to large areas of the body for long periods of time.
Adoring is different, as a non-steroidal topical treatment it may help control painful eczema symptoms over large areas of the body for longer periods of time.
Adults aged 18 years or older with Hidradenitis Suppurativa (HS) for at least 1 year, may qualify to participate. Individuals must have HS
lesions present in at least 2 distinct anatomic areas, as well as moderate to severe disease. Qualified participants must also have an inadequate
response to a course of appropriate oral antibiotics for treatment of HS, and have a total abscess and inflammatory nodule (AN) count of 5 or
During the placebo-controlled period, participants will receive investigational medication (active study drug), comparator medication, or placebo
via injection. During the active treatment period, participants will receive active study drug or comparator medication. Study medication and
study-related assessments will be provided at no cost. Reimbursement for study-related expenses will also be provided.
Total study duration lasts about 42 weeks and involves about 35 visits to the study center.